Literature DB >> 11001622

Evidence for altered Fragile-X mental retardation protein expression in response to behavioral stimulation.

S A Irwin1, R A Swain, C A Christmon, A Chakravarti, I J Weiler, W T Greenough.   

Abstract

The Fragile-X mental retardation protein, the protein absent in Fragile-X syndrome, is synthesized near synapses upon neurotransmitter activation. Humans and mice lacking this protein exhibit abnormal dendritic spine lengths and numbers. Here we investigated Fragile-X protein levels in animals exposed to behavioral paradigms that induce neuronal morphological change. Fragile-X protein immunoreactivity was examined in visual cortices of rats reared in a complex environment for 10 or 20 days, motor cortices of rats trained on motor-skill tasks for 3 or 7 days, and either visual or motor cortices of inactive controls. Rats exposed to a complex environment for 20 days or trained for 7 days on motor-skill tasks exhibited increased Fragile-X protein immunoreactivity in visual or motor cortices, respectively. These results provide the first evidence for a behaviorally induced alteration of Fragile-X protein expression and are compatible with previous findings suggesting synaptic regulation of its expression. These results also strengthen the association of Fragile-X mental retardation protein expression with the alteration of synaptic structure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001622

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  15 in total

Review 1.  Genetic effects on human cognition: lessons from the study of mental retardation syndromes.

Authors:  P Nokelainen; J Flint
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

Review 2.  Defects in translational regulation contributing to human cognitive and behavioral disease.

Authors:  J C Darnell
Journal:  Curr Opin Genet Dev       Date:  2011-07-19       Impact factor: 5.578

3.  Reduced activity-dependent protein levels in a mouse model of the fragile X premutation.

Authors:  Ramona E von Leden; Lindsey C Curley; Gian D Greenberg; Michael R Hunsaker; Rob Willemsen; Robert F Berman
Journal:  Neurobiol Learn Mem       Date:  2014-01-23       Impact factor: 2.877

4.  The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome.

Authors:  Samantha Portis; Brian Giunta; Demian Obregon; Jun Tan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-09-20

Review 5.  Influence of the NR3A subunit on NMDA receptor functions.

Authors:  Maile A Henson; Adam C Roberts; Isabel Pérez-Otaño; Benjamin D Philpot
Journal:  Prog Neurobiol       Date:  2010-01-25       Impact factor: 11.685

6.  Expression of fragile X mental retardation protein within the vocal control system of developing and adult male zebra finches.

Authors:  C Winograd; D Clayton; S Ceman
Journal:  Neuroscience       Date:  2008-09-09       Impact factor: 3.590

7.  Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses.

Authors:  Laura N Antar; Rownak Afroz; Jason B Dictenberg; Reed C Carroll; Gary J Bassell
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

8.  Metabotropic Glutamate Receptor and Fragile X Signaling in a Female Model of Escalated Aggression.

Authors:  Laura E Been; Kelsey M Moore; Bruce C Kennedy; Robert L Meisel
Journal:  Biol Psychiatry       Date:  2015-08-07       Impact factor: 13.382

9.  Dynamics of the fragile X mental retardation protein correlates with cellular and synaptic properties in primary auditory neurons following afferent deprivation.

Authors:  Xiaoyan Yu; Xiaoyu Wang; Hitomi Sakano; Diego A R Zorio; Yuan Wang
Journal:  J Comp Neurol       Date:  2020-06-27       Impact factor: 3.215

Review 10.  Fragile X mental retardation protein and synaptic plasticity.

Authors:  Michael S Sidorov; Benjamin D Auerbach; Mark F Bear
Journal:  Mol Brain       Date:  2013-04-08       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.